Fredag 6 December | 21:18:05 Europe / Stockholm

Prenumeration

Kalender

Tid*
2024-08-22 - Kvartalsrapport 2024-Q2
2024-04-25 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2024-04-24 - Årsstämma
2024-03-06 - Bokslutskommuniké 2023
2023-11-17 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-04-21 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2023-04-20 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-22 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2022-04-21 - Årsstämma
2022-03-03 - Bokslutskommuniké 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-16 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2021-04-15 - Årsstämma
2021-03-03 - Bokslutskommuniké 2020
2020-12-02 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-04-09 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2020-04-08 - Årsstämma
2020-02-27 - Bokslutskommuniké 2019
2019-08-28 - Kvartalsrapport 2019-Q2
2019-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2019-04-11 - Årsstämma
2019-03-12 - Extra Bolagsstämma 2019
2019-02-28 - Bokslutskommuniké 2018
2018-08-29 - Kvartalsrapport 2018-Q2
2018-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2018-04-11 - Årsstämma
2018-03-02 - Bokslutskommuniké 2017
2017-11-09 - Extra Bolagsstämma 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2017-04-11 - Årsstämma
2017-02-28 - Bokslutskommuniké 2016
2016-08-25 - Kvartalsrapport 2016-Q2
2016-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2016-04-11 - Årsstämma
2016-02-25 - Bokslutskommuniké 2015
2015-08-19 - Kvartalsrapport 2015-Q2
2015-04-10 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2015-04-09 - Årsstämma
2015-02-27 - Bokslutskommuniké 2014
2014-04-23 - Kvartalsrapport 2014-Q1
2014-03-05 - Bokslutskommuniké 2013

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriLäkemedel & Handel
Herantis Pharma är ett bioteknikbolag i klinisk fas som utvecklar sjukdomsmodifierande terapier för Parkinsons sjukdom. Bolagets ledande produkt HER-096 är en liten syntetisk kemisk peptidomimetisk molekyl utvecklad baserat på CDNF-proteinets aktiva plats. HER-096 kombinerar verkningsmekanismen för CDNF med subkutan administrering. Herantis Pharma grundades 2008 och har sitt huvudkontor i Esbo, Finland.
2024-06-19 20:15:00

Company release

Herantis Pharma Plc, Company release, 19 June 2024 at 9:15 p.m. EEST

Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (19 April 2024)

Herantis Pharma Plc (“Herantis”), has on June 19, 2024, received a notification from Sp-Rahastoyhtiö Oy according to which the total number of Herantis shares owned by the investment funds of Sp-Rahastoyhtiö Oy (Säästöpankki Kotimaa and Säästöpankki Pienyhtiöt) is above five (5) per cent. The notification was made pursuant to chapter 9, section 5 of the Securities Market Act on 2 May 2024. Under the transition rules of the act 163/2024 amending the Finnish Securities Market Act (Amending Act), a shareholder in a First North listed company is required to notify major holdings within two months from the entry into force of the Amending Act. The notification has been made based on said transition rules, and not an acquisition or disposal of shares.

Herantis has one series of shares in which each share carries one vote. The percentages and numbers indicate the shareholding on the date the Amending Act entered into force on 19 April 2024.

Total positions of Sp-Rahastoyhtiö Oy subject to the notification obligation:
 % of shares and voting rights (total of 7.A)% of shares and voting rights through financial instruments (total of 7.B)Total of both in % (7.A + 7.B)Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached5.48 5.4820,160,733
Position of previous notification (if applicable)    
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights

Class/type of shares

ISIN code (if possible)

Number of shares and voting rights % of shares and voting rights

Direct

(SMA 9:5)

Indirect

(SMA 9:6 and 9:7)

Direct

(SMA 9:5)

Indirect

(SMA 9:6 and 9:7)

FI40000878611,105,620 5.4840 
SUBTOTAL A 1,105,6205.4840
Information in relation to the person subject to the notification obligation
☒ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
☐ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name% of shares and voting rights% of shares and voting rights through financial instrumentsTotal of both
    

For more information, please contact:

Tone Kvåle, CFO

Tel: +47 915 19576

Email: ir@herantis.com

Certified Advisor:

UB Corporate Finance Oy,

Finland: +358 9 25 380 225

ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com